Are ApoB, Lp(a) and a CAC score better than a standard cholesterol panel for heart-risk assessment?
Claim attributed to Peter Attia and preventive-cardiology / longevity-medicine advocates who argue standard lipid panels miss true cardiovascular risk. , A mainstream preventive-cardiology position now close to longevity practice; the three tests are increasingly endorsed in guidelines, though they carry unequal weight.
Each test adds real prognostic information a standard panel misses, and ApoB is at least as good as (often better than) LDL-C. The framing holds, with the caveat that "better prediction" is not the same as a proven better treatment strategy.
Better at predicting risk is not the same as proven to make you live longer; no outcome trial has pitted a marker-guided strategy against a standard panel.
What it’s supposed to target
- ApoB (atherogenic particle number)
- Lipoprotein(a)
- Coronary artery calcium (CAC)
- Risk discordance
Standard panels measure LDL cholesterol, the cargo, but atherosclerosis tracks the number of atherogenic particles, and each one carries a single ApoB protein, so ApoB counts the particles directly and predicts risk at least as well as LDL-C, especially where the two disagree. Lp(a) is a mostly genetic, independent, causal driver of heart disease and aortic stenosis that a routine panel ignores, and a coronary calcium scan looks past prediction to the artery itself, scoring plaque that is actually there.
This is the rare longevity-medicine claim that largely holds. ApoB and Lp(a) are increasingly endorsed in cardiology guidelines, and CAC meaningfully reclassifies risk in intermediate-risk patients, so using them is better, not worse, than a cholesterol panel alone. The honest caveats are about proportion, not validity: ApoB adds incrementally over a good panel, CAC uses low-dose radiation and is not for the very young or already-treated, and Lp(a) still has few targeted therapies. Better tools, used in the right person, not magic numbers.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
HOLDS: atherosclerosis is driven by apoB-containing particles, each carrying one apoB, so apoB counts them directly.
HOLDS: LDL-C can mislead when particles are cholesterol-poor (insulin resistance, high triglycerides, treated patients), underestimating risk.
HOLDS: Lp(a) is largely genetic, causal, and invisible to a routine panel.
HOLDS: CAC images existing disease and reclassifies risk beyond any blood marker.
DOES NOT YET HOLD: that a marker-guided strategy lowers hard events more than an LDL-C strategy.
What the evidence actually shows
ApoB counts the particles that actually cause the disease
Atherosclerosis is driven by apoB-containing lipoproteins depositing cholesterol in the artery wall, and each particle carries exactly one apoB, so one measurement counts them all. A standard panel reports LDL-C (cholesterol mass), a usually-good proxy that misleads in discordance, when particles are cholesterol-poor and LDL-C looks fine but particle number is high. Pooling UK Biobank with two trials, Marston 2022 found that with markers assessed together, only apoB stayed significantly associated with myocardial infarction (HR 1.27 per SD, 95% CI 1.15-1.40); Sniderman's meta-analysis ranked apoB strongest (RR ~1.43) over LDL-C (~1.25).
Lp(a) and CAC add information a panel cannot
Lp(a) is a genetically fixed, LDL-like particle that diet and statins barely move; the 2022 EAS consensus calls high Lp(a) causal for ASCVD, aortic stenosis and mortality and urges measuring it once in every adult's lifetime, something a routine panel omits. A CAC score directly images calcified plaque: in MESA (Detrano 2008), each doubling raised major coronary-event risk by roughly 15 to 35% (any coronary event 18 to 39%), adding value over traditional risk factors and now guideline-endorsed to guide statin decisions in intermediate-risk patients. The three are complementary, not interchangeable.
Studies, graded, and who paid
Large biobank/trial pooling and meta-analysis rank apoB highest; strongest when it diverges from LDL-C.
Genetic (Mendelian) evidence makes the causal case robust; major societies advise measuring once.
MESA shows incremental prediction; guideline-endorsed for intermediate-risk statin decisions.
No head-to-head outcome RCT; superiority is about accuracy, not proven event reduction.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 1 | Marston 2022, JAMA Cardiology, UK Biobank + FOURIER/IMPROVE-IT pooling | Prospective cohort plus trial-population pooling | ~429,959 (biobank 389,529; trials 40,430) | Mixed UK Biobank public; FOURIER (Amgen) and IMPROVE-IT (Merck) industry; author pharma disclosures. Direction matches independent cohort data. | Observational/post-hoc; apoB association, not a marker-guided treatment trial. |
| 2 | Sniderman 2019, JAMA Cardiology, apoB narrative review | Narrative review with discordance analysis | Not applicable (synthesis) | Funding unknown COI not retrievable from abstract; Sniderman is a long-standing apoB proponent. | Rationale/mechanism, not primary outcome data. |
| 3 | Sniderman 2011, Circ Cardiovasc Qual Outcomes, lipid-marker meta-analysis | Meta-analysis of prospective studies | ~233,455 subjects, ~22,950 events | Funding unknown PubMed lists only 'Non-U.S. Gov't' support; no specific sponsor named. | Predictive ranking only; concordant with later independent biobank data. |
| 4 | Kronenberg 2022, European Heart Journal, EAS Lp(a) consensus | Expert consensus / evidence synthesis | Synthesis of observational + Mendelian-randomization data | Mixed Society document, no single sponsor; extensive author disclosures (Amgen, Sanofi, Novartis). Causal case rests on genetic evidence. | Consensus, not a trial; no approved specific Lp(a) therapy yet. |
| 5 | Detrano 2008, NEJM, MESA coronary calcium | Prospective population cohort | 6,722 asymptomatic adults, median 3.8-yr follow-up | Independent NHLBI/NIH grants (N01-HC-95159 to 95169); publicly funded, no commercial sponsor. | Predictive, not a randomized CAC-guided management trial. |
This is a case where longevity-medicine practice aligns with where cardiology is already moving; the live debate is implementation and cost-effectiveness, not whether the markers carry real information.
Unproven ≠ disproven
No randomized trial has compared an apoB-guided versus LDL-C-guided treatment strategy on hard events, so the superiority claim is about prediction accuracy, not proven outcome benefit of switching markers.
Where claim and evidence diverge
For Lp(a) the causal case is strong but the treatment loop is incomplete: no specific lowering drug is approved (pelacarsen, olpasiran still in outcome trials), so 'measure it' currently outruns 'and here is the proven treatment.'
The money trail
Key apoB reviews are by long-standing proponents and much cohort/consensus work carries pharma disclosures, but the Lp(a) causal case and the MESA CAC data rest on genetic and publicly-funded (NHLBI) evidence robust to that bias.
The honest read
The claim holds: these three tests add real, often superior risk information a standard panel misses. Use them selectively, not reflexively, and remember better measurement is not yet proven better treatment.
What would change this verdict
A large RCT showing an apoB- or CAC-guided strategy lowers hard cardiovascular events no more than a standard LDL-C strategy.
Evidence that the incremental reclassification from these tests does not change management or outcomes in real-world use.
Sources
- Marston NA, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction. JAMA Cardiology. 2022;7(3):250-256.
- Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287-1295.
- Sniderman AD, et al. A Meta-Analysis of LDL-C, Non-HDL-C, and Apolipoprotein B as Markers of Cardiovascular Risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337-345.
- Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: EAS consensus statement. European Heart Journal. 2022;43(39):3925-3946.
- Detrano R, et al. Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups (MESA). NEJM. 2008;358(13):1336-1345.
People also ask
- Is ApoB a better predictor of heart risk than LDL cholesterol?
- Yes. ApoB predicts cardiovascular risk at least as well as, and often better than, LDL-C, with the advantage largest when the two diverge. Large biobank and trial pooling plus meta-analysis consistently rank ApoB highest among standard lipid measures.
- Why should I get my Lp(a) tested at least once?
- Lp(a) is an independent, causal risk factor that a standard cholesterol panel does not measure. Genetic (Mendelian) evidence makes the causal case robust, and major societies advise measuring it once. Note no specific Lp(a)-lowering drug is yet approved.
- What does a coronary artery calcium (CAC) score add to blood tests?
- A CAC score refines and reclassifies risk beyond blood markers. MESA data show it adds incremental prediction, and guidelines endorse it to help decide on statins for people at intermediate risk. It is best used selectively, not reflexively.
- Do these markers actually help you live longer than a standard panel?
- Not proven. No head-to-head outcome trial has shown a marker-guided strategy reduces hard cardiovascular events more than a standard LDL-C strategy. The advantage is better prediction and accuracy, which is not the same as a proven better treatment.
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.